Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive Emergencies

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 262 participants.

Also called NCT04670809

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 262 participants (planned count) (from the registry)
Sponsor
Nanjing Yoko Biomedical Co., Ltd. (from the registry)
Registry
  • NCT NCT04670809
Other papers using this trial's data
  • Efficacy and safety of clevidipine emulsion injection compared with nicardipine in patients with hypertensive emergencies: a randomized, single-blind, positive-parallel-controlled, phase III clinical trial Journal of hypertension, 2026-01-01 DOI, PubMed 41231022

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04670809. Randomized; single masking; primary purpose treatment. Start 2020-07-27 (actual); primary completion 2021-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive Emergencies
Condition
Hypertensive Emergency
Intervention (Drug)
Clevidipine Butyrate Injection
Intervention (Drug)
Ncardipine Hydrochloride Injection
Lead sponsor
Nanjing Yoko Biomedical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04670809
Content hash
c72472d8d1ef0c5d03ad092c5516c774f31252849f8a3318eab4ebc7c9cdb6e7